Your session is about to expire
← Back to Search
Leukotriene Inhibitor
Montelukast for COVID-19
Phase 3
Waitlist Available
Led By Adrian Hernandez, MD
Research Sponsored by Susanna Naggie, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 7, 14, 28, 90, and 120
Awards & highlights
Pivotal Trial
Summary
This trial is testing existing safe drugs to see if they can help non-hospitalized people with mild to moderate COVID-19 feel better faster and avoid severe outcomes. Participants will receive the study drug and will report their symptoms remotely.
Who is the study for?
This trial is for people aged 30 or older who have tested positive for COVID-19 within the last 10 days and are experiencing symptoms like fatigue, cough, or fever. They must not be hospitalized currently or in the past 10 days and should not have any known allergies to the study drug.
What is being tested?
The ACTIV-6 trial is testing Montelukast, a repurposed medication, against a placebo to see if it can reduce symptoms in non-hospitalized patients with mild to moderate COVID-19. Participants will report their symptoms remotely without needing in-person visits unless necessary.
What are the potential side effects?
While specific side effects of Montelukast in this context aren't detailed here, common ones include headache, stomach pain, heartburn, upset stomach, nausea, diarrhea; serious side effects may occur but are rare.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 7, 14, 28, 90, and 120
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 7, 14, 28, 90, and 120
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Time to Sustained Recovery in Days
Secondary study objectives
Mean Days Benefit as Measured by the Symptom and Clinical Event Scale
Number of Participants at Each Score on the COVID Clinical Progression Scale at Day 14
Number of Participants at Each Score on the COVID Clinical Progression Scale at Day 28
+10 moreSide effects data
From 2005 Phase 4 trial • 99 Patients • NCT0018946216%
Cold/Upper Respiratory Infection
10%
Diarrhea
6%
Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
Montelukast
Placebo
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm F - MontelukastExperimental Treatment1 Intervention
Montelukast will be self-administered orally by each participant at a dose of 10 mg once a day for 14 days.
Group II: Arm F - PlaceboPlacebo Group1 Intervention
Placebo - appearance and size matched to active study drug.
Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Montelukast
2008
Completed Phase 4
~15460
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for COVID-19 include antiviral agents, immune response modulators, and symptom relief medications. Antiviral agents, such as nirmatrelvir/ritonavir (Paxlovid), work by inhibiting viral replication, thereby reducing the viral load in the body.
Immune response modulators, like dexamethasone, help to control the body's inflammatory response, which can prevent severe complications such as acute respiratory distress syndrome (ARDS). Symptom relief medications, including antipyretics and analgesics like acetaminophen, manage fever and pain, improving patient comfort.
These mechanisms are crucial as they target different aspects of the disease, from reducing viral proliferation to managing the immune response and alleviating symptoms, thereby providing a comprehensive approach to treatment.
Application of Traditional Chinese Medicine and Systems Pharmacology in Drug Prevention and Treatment against COVID-19.A Review on Repurposed Drugs and Vaccine Trials for Combating SARS CoV-2.
Application of Traditional Chinese Medicine and Systems Pharmacology in Drug Prevention and Treatment against COVID-19.A Review on Repurposed Drugs and Vaccine Trials for Combating SARS CoV-2.
Find a Location
Who is running the clinical trial?
Vanderbilt University Medical CenterOTHER
894 Previous Clinical Trials
933,130 Total Patients Enrolled
Susanna Naggie, MDLead Sponsor
7 Previous Clinical Trials
37,205 Total Patients Enrolled
National Center for Advancing Translational Sciences (NCATS)NIH
354 Previous Clinical Trials
407,804 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have been diagnosed with COVID-19 more than 10 days before the screening.You are at least 30 years old.You have tested positive for COVID-19 within the past 10 days.You have had two or more symptoms of a new infection, like feeling tired, having trouble breathing, or a fever, for less than a week.
Research Study Groups:
This trial has the following groups:- Group 1: Arm F - Placebo
- Group 2: Arm F - Montelukast
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger